Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 12, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13045-019-0813-7
Keywords
Chimeric antigen receptor T cells; Logic gate; Antigen escape; On-target; Off-tumor toxicities
Categories
Funding
- National Natural Science Foundation of China [81830002, 31870873]
- National Key Research and Development Program of China [2016YFC1303501, 2016YFC1303504, 2017YFC0909803]
Ask authors/readers for more resources
The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by antigen escape and on-target, off-tumor toxicities. Therefore, it may be a potentially effective strategy to select appropriate targets and to combine multi-antigen-targeted CAR-T cells with OR, AND and NOT Boolean logic gates. We summarize the current limitations of CAR-T cells as well as the efficacy and safety of logic-gated CAR-T cells in antitumor therapy. This review will help to explore more optimized strategies to expand the CAR-T cell therapeutic window.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available